The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10820 malaria professionals are enjoying the free benefits of MalariaWorld today

uncomplicated falciparum

Pharmacokinetic profile of amodiaquine and its active metabolite desethylamodiaquine in Ghanaian patients with uncomplicated falciparum malaria

January 9, 2021 - 13:17 -- Open Access
Tags: 
amodiaquine, uncomplicated falciparum, malaria, Ghana
Author(s): 
Thomas A. Anyorigiya, Sandra Castel, Karen I. Barnes, et al.
Reference: 
Malaria Journal 2021 20:18, 6 January 2021

Accurate measurement of anti-malarial drug concentrations in therapeutic efficacy studies is essential to distinguish between inadequate drug exposure and anti-malarial drug resistance, and to inform optimal anti-malarial dosing in key target population groups.

In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso

January 7, 2020 - 15:14 -- Open Access
Tags: 
In vivo/ex vivo, efficacy, artemether–lumefantrine, artesunate–amodiaquine, first-line treatment, uncomplicated falciparum, malaria, children, randomized controlled trial, Burkina Faso
Author(s): 
Moussa Lingani, Léa Nadège Bonkian, Halidou Tinto, et al.
Reference: 
Malaria Journal 2020 19:8, 6 January 2020

Artemisinin-based combination therapy (ACT) is recommended to improve malaria treatment efficacy and limit drug-resistant parasites selection in malaria endemic areas. 5 years after they were adopted, the efficacy and safety of artemether–lumefantrine (AL) and artesunate–amodiaquine (ASAQ), the first-line treatments for uncomplicated malaria were assessed in Burkina Faso.

Subscribe to RSS - uncomplicated falciparum